Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bioventus (BVS) EBITDA Margin (2020 - 2025)

Bioventus (BVS) has disclosed EBITDA Margin for 6 consecutive years, with 7.94% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 1268.0% year-over-year to 7.94%, compared with a TTM value of 4.12% through Dec 2025, up 1178.0%, and an annual FY2025 reading of 4.12%, up 1306.0% over the prior year.
  • EBITDA Margin was 7.94% for Q4 2025 at Bioventus, up from 3.06% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 29.08% in Q2 2021 and bottomed at 116.44% in Q2 2023.
  • Average EBITDA Margin over 5 years is 9.72%, with a median of 4.27% recorded in 2024.
  • The sharpest move saw EBITDA Margin tumbled -10357bps in 2023, then soared 11105bps in 2024.
  • Year by year, EBITDA Margin stood at 6.75% in 2021, then crashed by -261bps to 24.4% in 2022, then surged by 197bps to 23.63% in 2023, then tumbled by -120bps to 4.74% in 2024, then skyrocketed by 268bps to 7.94% in 2025.
  • Business Quant data shows EBITDA Margin for BVS at 7.94% in Q4 2025, 3.06% in Q3 2025, and 5.92% in Q2 2025.